Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.

Roger M, Chaussain JL, Berlier P, Bost M, Canlorbe P, Colle M, Francois R, Garandeau P, Lahlou N, Morel Y

The Journal of clinical endocrinology and metabolism1 Apr 1986Cited by 62 (Europe PMC)

PMID2936759DOI10.1210/jcem-62-4-670PepBankPUB-02936759

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with precocious puberty, growth velocity decreased significantly during triptorelin treatment.
In plain wordsIn children with early puberty, growth slowed during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseGrowth velocity
Study
n = 26
Outcome group
Linear growth · Reproductive and sexual health
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Source sentences
Summary
In both sexes, growth velocity decreased significantly, and bone maturation was generally reduced.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675906
02HumanNon-randomized trialEfficacy outcome
In children with precocious puberty, bone maturation generally decreased during triptorelin treatment.
In plain wordsIn children with early puberty, bones generally matured more slowly during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone maturation
Study
n = 26
Outcome group
Bone and joint · Musculoskeletal
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Source sentences
Summary
In both sexes, growth velocity decreased significantly, and bone maturation was generally reduced.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675907
03HumanNon-randomized trialEfficacy outcome
In children with precocious puberty, FSH decreased significantly within 3 weeks of triptorelin treatment.
In plain wordsIn children with early puberty, FSH decreased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseFSH
Study
n = 26
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Source sentences
Summary
Plasma levels of estradiol or testosterone and FSH levels decreased significantly within 3 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675910
04HumanNon-randomized trialEfficacy outcome
In children with precocious puberty, LH responses to LHRH decreased to normal prepubertal values after 7 weeks of triptorelin.
In plain wordsIn children with early puberty, triptorelin reduced LH responses to levels normal before puberty.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseLH response to LHRH
Study
n = 26
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Source sentences
Summary
The LH response to LHRH was reduced to normal prepubertal values after 7 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675911
05HumanNon-randomized trialEfficacy outcome
In children with precocious puberty, no secondary clinical or biochemical escape occurred during triptorelin treatment.
In plain wordsIn children with early puberty, treatment suppression persisted without clinical or laboratory escape.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeClinical or biochemical escape
Study
n = 26
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Source sentences
Summary
No secondary clinical or biochemical escape occurred.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675912
06HumanNon-randomized trialSafety outcome
In children receiving triptorelin, no antibodies to the agonist were detected in serum.
In plain wordsIn children receiving triptorelin, tests detected no antibodies against the drug.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeAnti-triptorelin antibodies
Study
n = 26
Outcome group
Immune response · Immune and inflammation
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Source sentences
Summary
No antibodies to LHRH-A were detected in the patients' sera.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675916
07HumanNon-randomized trialEfficacy outcome
In girls with precocious puberty, breast enlargement disappeared during triptorelin treatment.
In plain wordsIn girls with early puberty, breast enlargement disappeared during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBreast enlargement
Study
n = 16
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Source sentences
Summary
In girls, breast enlargement disappeared, and mean uterus size decreased from 44.4 +/- 2.5 to 38.1 +/- 3.1 mm (mean +/- SEM; P less than 0.02) within 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675902
08HumanNon-randomized trialEfficacy outcome
In girls with precocious puberty, mean uterus size decreased from 44.4 to 38.1 mm within 6 months of triptorelin treatment.
In plain wordsIn girls with early puberty, uterus size decreased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseUterus size
Study
n = 16
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Measurements
Mean uterus size
44.4 mm
baseline
Mean uterus size
38.1 mm
within 6 months
Source sentences
Summary
In girls, breast enlargement disappeared, and mean uterus size decreased from 44.4 +/- 2.5 to 38.1 +/- 3.1 mm (mean +/- SEM; P less than 0.02) within 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675903
09HumanNon-randomized trialEfficacy outcome
In girls with precocious puberty, mean ovary length decreased from 23.0 to 16.2 mm during triptorelin treatment.
In plain wordsIn girls with early puberty, ovary length decreased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseOvary length
Study
n = 16
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Measurements
Mean ovary length
23 mm
baseline
Mean ovary length
16.2 mm
during treatment
Source sentences
Summary
Mean ovary length decreased from 23.0 +/- 1.5 to 16.2 +/- 1.5 mm (P less than 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675904
10HumanNon-randomized trialEfficacy outcome
In girls with precocious puberty, estradiol decreased significantly within 3 weeks of triptorelin treatment.
In plain wordsIn girls with early puberty, estradiol decreased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseEstradiol
Study
n = 16
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Source sentences
Summary
Plasma levels of estradiol or testosterone and FSH levels decreased significantly within 3 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675908
11HumanNon-randomized trialSafety outcome
In girls with precocious puberty, transient vaginal bleeding occurred after the first or second triptorelin injection.
In plain wordsIn girls with early puberty, temporary vaginal bleeding occurred after an early triptorelin injection.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTransient vaginal bleeding
Study
n = 16
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Source sentences
Summary
No side-effects occurred, except for transient vaginal bleeding in girls after the first or second injection.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675914
12HumanNon-randomized trialPharmacokinetics
In children with precocious puberty, mean plasma triptorelin concentrations were 295, 218, 215 and 224 pg/ml on days 3, 7, 14 and 21.
In plain wordsIn children with early puberty, plasma triptorelin remained measurable through day 21.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicablePlasma triptorelin concentrations
Study
n = 13
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Measurements
Mean plasma concentration
295 pg/ml
day 3
Mean plasma concentration
218 pg/ml
day 7
Mean plasma concentration
215 pg/ml
day 14
Mean plasma concentration
224 pg/ml
day 21
Source sentences
Summary
On days 3, 7, 14, and 21, mean concentrations (+/- SEM) were 295 +/- 44, 218 +/- 31, 215 +/- 45, and 224 +/- 39 pg/ml, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Plasma LHRH-A levels were measured in 13 children by means of a specific RIA.
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675901
13HumanNon-randomized trialEfficacy outcome
In boys with precocious puberty, mean testis volume decreased from 8.1 to 6.7 ml within 6 months of triptorelin treatment.
In plain wordsIn boys with early puberty, testis volume decreased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseTestis volume
Study
n = 10
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Measurements
Mean testis volume
8.1 ml
baseline
Mean testis volume
6.7 ml
within 6 months
Source sentences
Summary
In boys, mean testis volume decreased from 8.1 +/- 1.2 to 6.7 +/- 1.2 ml (P less than 0.02) within 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675905
14HumanNon-randomized trialEfficacy outcome
In boys with precocious puberty, testosterone decreased significantly within 3 weeks of triptorelin treatment.
In plain wordsIn boys with early puberty, testosterone decreased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseTestosterone
Study
n = 10
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Source sentences
Summary
Plasma levels of estradiol or testosterone and FSH levels decreased significantly within 3 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675909
15HumanNon-randomized trialEfficacy outcome
In one boy, biological features of puberty recurred within 1 month after omission of the fifth triptorelin injection.
In plain wordsIn one boy, puberty returned after a missed triptorelin injection.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseRecurrence after missed injection
Study
n = 1
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
60 micrograms/kg on days 1 and 21, then every 4 weeks · intramuscular · 10-27 monthsAs given in this study (human).
Source sentences
Summary
In 1 boy, all biological features of puberty recurred within 1 month after omission of the fifth injection.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of a delayed release formulation of the LHRH agonist D-Trp6-LHRH (LHRH-A; im microcapsules) were tested in 16 girls, 0.9-8.8 yr old, and 10 boys, 2.0-10.5 yr old, with precocious puberty.
Summary · context
Sixty micrograms of LHRH-A/kg BW were given im on days 1 and 21 and thereafter every 4 weeks for 10-27 months.
Report a problemFND-0293675913

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.